Anti-Cancer Drug Design

Protein kinase antagonists: interim challenges and issues
pp. 1-2(2)
Author: Sausville E.

Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer
pp. 3-16(14)
Author: Fry D.

PKC412 - a protein kinase inhibitor with a broad therapeutic potential
pp. 17-28(12)
Authors: Fabbro D.; Ruetz S.; Bodis S.; Pruschy M.; Csermak K.; Man A.; Campochiaro P.; Wood J.; O'Reilly T.; Meyer T.

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
pp. 29-41(13)
Authors: Mendel D.; Laird A.; Smolich B.; Blake R.; Liang C.; Hannah A.; Shaheen R.; Ellis L.; Weitman S.; Shawver L.; Cherrington J.

UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century?
pp. 43-52(10)
Authors: Akinaga S.; Sugiyama K.; Akiyama T.

Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition
pp. 53-66(14)
Authors: Gussio R.; Zaharevitz D.; McGrath C.; Pattabiraman N.; Kellog G.; Schultz C.; Link A.; Kunick C.; Leost M.; Meijer L.; Sausville E.

Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications
pp. 67-72(6)
Authors: Girnita L.; Wang M.; Xie Y.; Nilsson G.; Dricu A.; Wejde J.; Larsson O.

A rational design of bioactive taxanes with side chains situated elsewhere than on C-13
pp. 73-78(6)
Authors: Wu J.; Zamir L.